Antibody-directed enzyme prodrug therapy (ADEPT): Evidence for a bystander effect in vitro

International Journal of Oncology

Volumn 9, Issue 3, 1996, Pages 567-570

  Retta, Beide Mariam Ejigu ^a   Burke, Philip J ^a   Photiou, Andrew ^a   Melton, Roger G ^b   Eno Amooquaye, Ebun ^a  

^a CHARING CROSS HOSPITAL   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

ADEPT; bystander effect; prodrug

Indexed keywords

CARBOXYPEPTIDASE G2; IMMUNOGLOBULIN F(AB')2 FRAGMENT;

ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ARTICLE; COLON CANCER; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG MIXTURE; DRUG RELEASE; ENZYME THERAPY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; PRIORITY JOURNAL;

EID: 0029810013     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Bagshawe KD, Sharma SK, Springer CJ and Rogers GT: Antibody directed enzyme prodrug therapy (ADEPT). A review of some theoretical, experimental and clinical aspects. Ann Oncol 5: 879-891, 1994.
2. Kerr DE, Schreiber GJ, Vrudhula VM, Svensson HP, Hellstrom I, Hellstrom KE and Senter PD: Regressions and cures of melanoma xenografts following/treatment with monoclonal antibody ß-lactamase conjugates in combination with anticancer prodrugs. Cancer Res 55: 3558-3563, 1995.
3. Blakey DC, Davies DH, Dowell RI, East SJ, Burke PJ, Sharma SK, Springer CJ, Mauger AB and Melton RG: Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs. Br J Cancer 72: 1083-1088, 1995.
4. Svensson HP, Vrudhula VM, Emswiler JE, MacMaster JF, Cosand WL, Senter PD and Wallace PM: In vitro and in vivo activities of a doxorubicin prodrug in combination with monoclonal antibody ß-lactamase conjugates. Cancer Res 55: 2357-2365, 1995.
5. Wallace PM, MacMaster JF, Smith VF, Kerr DE, Senter PD and Cosand WL: Intratumoral generation of 5-fluorouracil mediated by an antibody-cytosine deaminase conjugate in combination with 5-fluorocytosine. Cancer Res 54: 2719-2723, 1994.
6. Eccles SA, Court WJ, Box GA, Dean CJ, Melton RG and Springer CJ: Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbR-2 p185. Cancer Res 54: 5171-5177, 1994.
7. Bagshawe KD, Sharma SK, Springer CJ and Antoniw P: Antibody-directed enzyme prodrug therapy: a pilot scale clinical trial. Tumor Targeting 1: 17-29, 1995.
8. Sahin U, Hartmann F, Senter P, Pohl C, Engert A, Diehl V and Pfreundschuh M: Specific activation of the prodrug mitomycin phosphate by a bispecific anti-CD30/anti-alkaline phosphatase monoclonal antibody. Cancer Res 50: 6944-6948, 1990.
9. Dowell R, Springer CJ, Davies DH, Hadley EM, Burke PJ, Boyle FT, Melton RG, Connors TA, Blakey DC and Mauger AB: New mustard prodrugs for antibody-directed enzyme prodrug therapy (ADEPT): alternative to the amide link. J Med Chem 39: 1100-1105, 1996.
10. Melton RG, Boyle JMB, Rogers GT, Burke PJ, Bagshawe KD and Sherwood RF: Optimisation of small-scale coupling of A5B7 monoclonal antibody to carboxypeptidase G2. J Immunol Methods 158: 49-56, 1993.
11. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica J, Warren JT, Bokesch H, Kenney S and Boyd MR: New colorimetric cytotoxicity assay for anti-cancer drug screening. J Natl Cancer Inst 82: 1107-1112, 1990.
12. Blakey DC, Valcaccia BE, East S, Wright AF, Boyle FT, Springer CJ, Burke PJ, Melton RG and Bagshawe KD: Antitumour effects of an antibody-carboxypeptidase G2 conjugate in combination with a benzoic acid mustard prodrug. Cell Biophys 222: 1-8, 1993.
13. Springer CJ, Dowell R, Burke PJ, Hadley E, Davies DH, Blakey DC, Melton RG and Niculescu-Duvaz I: Optimisation of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for ADEPT. J Med Chem 38: 5051-5065, 1996.